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Background: Human epidermal growth factor receptor 2 (HER2) is considered to be a 
therapeutic and prognostic marker in the management of breast carcinoma (BC), although discor-
dance rates between primary and metastatic or locally recurrent lesions have been reported.
Methods: One hundred and forty-eight paraffin-embedded BC tissues from patients of mean 
age 59.27 (33–96) years and corresponding synchronous lymph node metastases were collected 
and retrospectively studied using immunohistochemistry and fluorescence in situ hybridization 
to evaluate HER2 status. Fleiss-Cohen weighted k statistics were used to assess the concordance 
rate between HER2 status of the primary BC and the synchronous metastatic lesions.
Results: The overall concordance rate for HER2 was 95.28%. Eighty-nine cases were concor-
dantly HER2-negative in primary BC and nodal metastases, and 52 cases were HER2-positive 
in both primary and metastatic tumors. Changes in HER2 status between primary BC and corre-
sponding synchronous metastases were observed in seven (4.72%) cases. Three of the discordant 
cases were HER2-negative in the primary tumor and HER2-positive in the metastases, while 
four cases were HER2-positive in the primary BC and HER2-negative in the metastases. No 
significant correlations were identified between HER2 status and expression of hormone recep-
tors, growth fraction (Ki-67), or other histopathological parameters (pT, pN, grade).
Conclusion: Simultaneous determination of HER2 in BC and corresponding metastatic lymph 
nodes is not mandatory, but may strongly influence the therapeutic management. It was demon-
strated that loss of HER2 amplification results in worse post-relapse survival and overall survival 
in BC patients and, on the other hand, a gain in HER2 expression in metastatic lymph nodes 
of BC may allow the possibility of a targeted treatment. Thus, our opinion is that significant 
prognostic information may be obtained by simultaneous assessment of HER2 status in both 
primary and synchronous metastatic BC.
Keywords: human epidermal growth factor receptor 2, breast cancer, synchronous lymph 
nodes, metastases, prognosis
Introduction
Assessment of human epidermal growth factor receptor 2 (HER2) status in patients 
with breast carcinoma (BC) is commonly performed using neoplastic tissue from the 
primary tumor. However, in recent years, several papers have shown that HER2 status 
may be different in metastatic lesions when compared with the primary tumor,1–6 and 
this discrepancy is more frequently found in distant metastases than in locoregional 
ones.7,8 Discordance in HER2 status may be found not only between primary BC and 
its metastases, but also between consecutive relapses of the same tumor, with similar 
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proportions of cases turning from negative to positive and 
vice versa, with such a change occurring mainly in second 
or subsequent progressions.9
The possible divergence in HER2 status between the 
primary BC and its metastases, or in consecutive metasta-
ses of the same tumor, is significant because it may modify 
a patient’s sensitivity to targeted therapy,6 which might 
be appropriate for the primary tumor but not for metastases 
and vice versa.10–13 For this reason, some authors have sug-
gested that HER2 status should be reassessed in metastatic 
BC tumor tissue to establish if a particular therapy is actually 
appropriate.1,4–6,12,14
The reasons underlying changes in HER2 status in metas-
tases when compared with the primary BC have not yet been 
clarified. Nonetheless, in most of the studies, primary BC was 
compared with recurrent or metachronous lesions.2,4,12,13,15–18 
Discordance between primary and metachronous tumors 
may occur for a variety of reasons, including variability in 
technical assessment or preanalytical factors, such as use of 
different fixation intervals and procedures,19–21 or biological 
modifications during tumor progression. In addition, if the 
patient undergoes chemotherapy, metachronous tumors may 
show polyploidization in tumor cells as a treatment-related 
effect, which may be misinterpreted as HER2 amplification, 
with the potential for false positive results.22
In the comparison between primary tumor and paired 
synchronous lymph node metastases, the possibility that 
variability in HER2 status might depend on external factors 
is reduced, as both the specimens may be collected during the 
same surgical procedure, prior to any influence of therapy, and 
submitted to the same fixation methodology. Thus, analysis of 
the concordance rate between primary BC and synchronous 
metastases could provide more information on the biological 
processes underlying changes in HER2 status. However, to the 
best of our knowledge, the few studies that have investigated 
modification of HER2 status in paired samples of primary BC 
and synchronous node metastases were only performed using 
tissue microarrays.1,23,24 Thus, in order to minimize the prob-
ability of technical sampling errors due to the tissue microar-
ray approach, in the present study we retrospectively analyzed 
HER2 variation in a cohort of primary BC and synchronous 
nodal metastases by using whole sections of the tumors.
Materials and methods
One hundred and forty-eight surgical BC specimens from 
patients of mean age 59.27 (33–96) years and corresponding 
synchronous lymph node metastases were retrospectively 
collected from five separate anatomic pathology units in Italy. 
None of the patients had received neoadjuvant chemotherapy 
or other therapies prior to surgical resection.
Data on the histotype, grading, hormone receptor expres-
sion, growth fraction (Ki67 labelling index), and HER2 status 
were available in all cases. Personal patient details were non-
identifiable and all patients had provided written consent to 
their medical information being used for research purposes, 
in accordance with the Declaration of Helsinki. Approval for 
this retrospective study was obtained from the local ethics 
committees of the universities of Messina, Catania, Salerno, 
Perugia, and Palermo, Italy.
For each case, 4 µm-thick sections from the formalin-
fixed paraffin-embedded representative tissue blocks of 
primary tumor and nodal metastases were set for HER2 
immunohistochemistry. HER2 expression was investigated 
in all the nodal metastases; at least three metastatic lymph 
nodes were tested for each case.
The immunohistochemical analysis for evaluation of 
HER2 status was carried out using the HercepTest™ kit 
(Dako, Glostrup, Denmark) with an automated procedure 
(Autostainer Link 48, Dako), according to the  manufacturer’s 
instructions. The same procedure was applied at all of the 
units, with HER2 positivity defined as 3+ when strong 
membranous staining was noted in at least 30% of cells, 
2+ when weak to moderate complete membranous staining 
was evident in 10%–30% of tumor cells, 1+ when a faint or 
weak and incomplete membrane staining was observed, and 
0 when no staining was observed or when staining was pres-
ent in less than 10% of neoplastic cells. Fluorescence in situ 
hybridization (FISH) analysis was performed using a HER2 
FISH PharmDx™ kit (Dako) in cases showing 2+ immu-
nostaining, and gene amplification was recorded when the 
HER2/centromeric probe for chromosome 17 signal ratio was 
$2.0. In order to avoid significant interobserver variability in 
HER2 immunohistochemical scoring, we selected a majority 
(140/148) of specimens with an easily attributable score, such 
as 3+ (56/148) or 0 (84/148); in fact, these latter two catego-
ries  represent the more reproducible scores in BC, the first 
certainly positive and the second certainly negative, that may 
greatly limit the interobserver judgment impair. After a first 
assessment in each unit of pathology, all the immunostained 
slides were reassessed, in a random order, by two observers 
(AI and GT), blinded of previous paired data. In the event of 
disagreement, cases were jointly discussed using a double-
headed microscope until agreement was reached.
Fleiss-Cohen weighted k statistics were used to assess 
concordance between the HER2 status of the primary BC 
and metastatic synchronous lesions; k values of 0–0.2 were 
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regarded as no agreement, 0.21–0.4 as fair agreement, 
0.41–0.6 as moderate agreement, 0.61–0.8 as substan-
tial agreement, and 0.81–1 as almost perfect agreement. 
 Statistical correlations between HER2 status and the other 
histopathological parameters were investigated using the 
chi-squared test. A P-value ,0.05 was considered to be sta-
tistically significant. The data were analyzed using Statistical 
Package for the Social Sciences version 6.1.3 software (SPSS 
Inc., Chicago, IL, USA).
Results
The histopathological characteristics and immunohistochem-
istry of cases included in the study are summarized in Table 1. 
With reference to the histotype, all primary BCs had been 
diagnosed as ductal invasive carcinomas, with the following 
 grading: five G1 (3.39%), 65 G2 (43.91%), and 78 G3 (52.70%). 
According to pTNM staging, 56 cases had been classified as 
pT1 (37.83%), 62 as pT2 (41.89%), 17 as pT3 (11.48%), and 
13 as pT4 (8.80%), while N status was N1 in 58 cases (39.18%), 
N2 in 60 (40.55%) and N3 in 30 (20.27%).
 With regard to HER2 immunohistochemistry, 56 (37.84%) 
primary BCs had a score of 3+, 84 (56.76%) scored 0 
(no staining), while six (4.05%) were scored as 2+ and two 
(1.35%) as 1+. FISH analysis revealed no amplification in all 
cases scored as 2+. FISH was carried out in both the 1+ cases 
since these carcinomas showed high-grade, high Ki67 value, 
N+ status, and an absence of endocrine receptor expression, 
but no HER2 amplification was identified.
Thus, among the primary BCs, HER2 was considered 
as amplified in 56 cases (37.84%) and not amplified in 
92 cases (62.16%), the latter representing the total number of 
cases scored as 0, 1+, and 2+, all of which were FISH-negative 
(Table 1). When the synchronous nodal metastases were con-
sidered, HER2 was scored as 3+ in 55 cases, while 93 cases 
were HER2-negative. No gene amplification was found when 
FISH analysis was carried out in the 1+ tumors. The k value 
for concordance in HER2 status between the primary tumors 
and metastases was 0.87 (almost perfect agreement).
The overall concordance rate was 95.28%; specifically, 89 
cases were concordantly HER2-negative in primary BC and in 
nodal metastases, while 52 cases were HER2-positive in both 
primary and metastatic tumors (Table 1). Changes in HER2 sta-
tus between primary BC and corresponding synchronous metas-
tases were evident in seven (4.72%) cases (Table 2). Three of the 
discordant cases were HER2-negative in the primary tumor and 
positive in the metastases, while four cases were HER2-positive 
Table 1 histopathological characteristics and biomolecular phenotypes of primary breast cancer and lymph node metastases
Parameter Cases  
(n)
HER2+ tumors HER2- tumors
n Node 
concordance 
(T/N = +/+)
Node 
discordance 
(T/N = +/-)
P-values n Node 
concordance 
(T/N = -/-)
Node 
discordance 
(T/N = -/+)
P-values
her2 status 148 56 52 (92.9%) 4 (7.1%) – 92 89 (96.7%) 3 (3.3%) –
pT 0.774 0.619
 T1 56 20 19 1 37 36 1
 T2 62 24 22 2 37 36 1
 T3 17 7 6 1 10 9 1
 T4 13 5 5 0 8 8 0
pn 0.815 0.545
 n1 58 22 21 1 36 34 2
 n2 60 21 19 2 40 39 1
 n3 30 13 12 1 16 16 0
grade 0.481 0.690
 g1 5 0 0 0 5 5 0
 g2 65 19 17 2 47 46 1
 g3 78 37 35 2 40 38 2
er status 0.335 0.496
 er+ 108 29 26 3 80 77 3
 er- 40 27 26 1 12 12 0
Pr status 0.153 0.475
 Pr+ 100 23 20 3 79 76 3
 Pr- 48 33 32 1 13 13 0
Ki-67 0.397 0.747
 Ki-67 #14% 46 8 8 0 39 38 1
 Ki-67 .14% 102 48 44 4 53 51 2
Abbreviations: er, estrogen receptor; Pr, progesterone receptor; her2, human epidermal growth factor receptor 2; pT, post-surgical tumor size; pn, post-surgical node status.
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in the primary BC and HER2-negative in the metastases. No 
significant correlations emerged between HER2 status and 
expression of hormone receptors, growth fraction (Ki-67), or 
other histopathological parameters (pT, pN, grade).
Discussion
Although HER2 status is generally considered to be stable during 
the metastatic process, with a high concordance rate between 
primary tumors and metastases, many reports have shown a 
clinically significant HER2 discordance, ranging between 0% 
and 34%, when comparing primary and recurrent or metastatic 
BC.1,2,4,12,13,15–18,25,26 The reported modification in HER2 status 
is from positive to negative, but has also been reported in the 
opposite direction,2 although the prevalence of HER2-negative 
conversion outnumbers that of HER2-positive conversion.4 Of 
note is that the analyses concerning HER2 changes have been 
preferentially performed in recurrent locoregional or metachro-
nous breast lesions,2,4,12,13,15–18 while a quantitative analysis of 
HER2 modifications in small cohorts of paired primary BC 
and synchronous node metastases were exclusively performed 
on tissue microarrays, with conflicting reports.1,23–25 For this 
reason, in the present study, we retrospectively analyzed whole 
sections of original breast tumor and metastatic lymph node 
tissue, with a conspicuous reduction of error in the technical 
sampling as occurs by tissue microarray approach. Moreover, 
the use of paired samples of BC and lymph nodes collected 
during the same surgical procedure and subjected to the same 
fixation methodology avoided technical variability and therefore, 
immunohistochemical results, being always reproducible in pri-
mary and metastatic lesions, may not determine any unjustified 
change in the targeted therapeutic management.
It has been stressed that higher discordance is found using 
immunohistochemistry for the determination of HER2 status 
than when using FISH, suggesting that methodology may play 
a significant role in the discordance.2,26 Indeed, when the same 
tumors were tested by both immunohistochemistry and FISH, 
the discordance rate was 18% using immunohistochemistry 
and 12% by FISH.13,27 In our opinion, this discrepancy could 
be minimized if only 3+ scored or FISH+ cases are considered 
as amplified for HER2, since this could avoid the need for a 
central review of the specimens, as has been proposed pre-
viously.28 Hence, for the present analysis, we mainly selected 
frankly positive (3+) or negative (0) cases, since this may 
reduce the bias connected with the reproducibility of HER2 
determination. Indeed, when all the cases were finally reas-
sessed by two observers blinded to the previous paired data, 
the only disagreement that arose involved cases showing a 
2+ or 1+ score that were tested by FISH. Thus, we may sup-
pose that the HER2 discordance rate of 4.72% between the 
primary BC and their synchronous nodal metastases could 
not be due to doubtful HER2 assessment. In accordance with 
the relevant literature, we found both positive and negative 
conversion of HER2 status between the primary tumor and 
the lymph node metastases.1,25,28,29
Our discordance rate was lower than that reported for locore-
gional recurrences and metachronous metastases,2,4,13,15,16,18 
but quite similar to the figure of 3.4% reported for metastatic 
lymph nodes by tissue microarrays,23 although other recent 
studies have shown very different discordance rates for HER2 
expression, ranging between 0% and 9% in archival paired 
tissue microarray material.23,30
The conversion in HER2 status is consistent with the evi-
dence that HER2 gene amplification can be acquired during 
disease progression or recurrence in BC patients.31,32 Indeed, 
breast tumor cells may have different pathophysiological states, 
divide continuously, and harbor the potential for further muta-
tions. In addition, during progression of BC, different clones 
may coexist as a consequence of increasing genetic instability, 
and metastatic cells from a HER2-negative primary tumor may 
undergo amplification during neoplastic spread in an axillary 
lymph node. On the other hand, the possibility of negative 
conversion for HER2 in metastatic deposits should not be 
exclusively attributed to the phenomenon of resistance during 
trastuzumab therapy, since our patients had not been subjected 
to neoadjuvant treatment. However, anti-HER2 therapy may be 
ineffective in these patients, although it would be worthwhile 
collecting more information on larger cohorts.
Conclusion
Our multicenter retrospective analysis confirms that discor-
dance in HER2 status may be present between primary BC 
Table 2 seven cases with changes in her2 status between the 
primary Bc and corresponding synchronous nodal metastases
pT pN Grading ER% PR% Ki-67% HER2 
primary 
lesions
HER2 
metastatic 
lesions
T2 n3 g3 90 15 20 3+ 0
T3 n2 g2 25 70 15 3+ 0
T2 n2 g3 0 0 30 3+ 0
T1c n1 g2 80 80 35 3+ 1+*
T1c n1 g3 90 30 15 0 3+
T2 n2 g3 0 0 35 1+* 3+
T3 n1 g2 0 0 20 0 3+
Notes: *Not amplified by fluorescence in situ hybridization. T1c is a variant of pT1 
tumours, with a neoplastic dimension ranging from 1.5 to 2.0 cm.
Abbreviations: er, estrogen receptor; Pr, progesterone receptor; her2, human 
epidermal growth factor receptor 2; pT, post-surgical tumor size; pn, post-surgical 
node status; Bc, breast carcinoma.
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and synchronous axillary metastatic lymph nodes. Although 
simultaneous determination of HER2 and hormone receptors 
in BC and corresponding metastatic lymph nodes is not manda-
tory at present, the finding that synchronous metastases from 
BC may have a different status when compared with markers 
from the primary tumor is important. Indeed, this may strongly 
influence therapeutic management and perhaps impact the 
prognosis for patients, given that it was demonstrated that loss 
of HER2 amplification results in worse post-relapse and overall 
survival in BC patients,13,17 and on the other hand, a gain in 
HER2 expression in metastatic lymph nodes in BC may allow 
the possibility of a targeted treatment. Thus, our opinion is 
that significant prognostic information can be obtained from 
analysis of HER2 status in synchronous metastatic lymph 
nodes, although further prospective studies are needed to verify 
the clinical significance of simultaneous assessment of HER2 
status in both primary and synchronous metastatic BC.
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